Purpose: Prior to 90 Y hepatic radioembolization, a dosage of 99m Tc-macroaggregated albumin ( 99m Tc-MAA) is administered to simulate the distribution of the 90 Y-loaded microspheres. This pretreatment procedure enables lung shunt estimation, detection of potential extrahepatic depositions, and estimation of the intrahepatic dose distribution. However, the predictive accuracy of the MAA particle distribution is often limited. Ideally, 90 Y microspheres would also be used for the pretreatment procedure. Based on previous research, the pretreatment activity should be limited to the estimated safety threshold of 100 MBq, making imaging challenging. The purpose of this study was to evaluate the quality of intra-and extrahepatic imaging of 90 Y-based pretreatment positron emission tomography/computed tomography (PET/CT) and quantitative single photon emission computed tomography (SPECT)/CT scans, by means of phantom experiments and a patient study. Methods: An anthropomorphic phantom with three extrahepatic depositions was filled with 90 Y chloride to simulate a lung shunt fraction (LSF) of 5.3% and a tumor to nontumor ratio (T/N) of 7.9. PET /CT (Siemens Biograph mCT) and Bremsstrahlung SPECT/CT (Siemens Symbia T16) images were acquired at activities ranging from 1999 MBq down to 24 MBq, representing post-and pretreatment activities. PET/CT images were reconstructed with the clinical protocol and SPECT/CT images were reconstructed with a quantitative Monte Carlo-based reconstruction protocol. Estimated LSF, T/N, contrast to noise ratio of all extrahepatic depositions, and liver parenchymal and tumor dose were compared with the phantom ground truth. A clinically reconstructed SPECT/CT of 150 MBq 99m Tc represented the current clinical standard. In addition, a 90 Y pretreatment scan was simulated for a patient by acquiring posttreatment PET/CT and SPECT/CT data with shortened acquisition times. Results: At an activity of 100 MBq 90 Y, PET/CT overestimated LSF [+10 percentage point (pp)], underestimated liver parenchymal dose (À3 Gy/GBq), and could not detect the extrahepatic depositions. SPECT/CT more accurately estimated LSF (À0.7 pp), parenchymal dose (À0.3 Gy/GBq) and could detect all three extrahepatic depositions. 99m Tc SPECT/CT showed similar accuracy as 90 Y SPECT/CT (LSF: +0.2 pp, parenchymal dose: +0.4 Gy/GBq, all extrahepatic depositions visible), although the noise level in the liver compartment was considerably lower for 99m Tc SPECT/CT compared to 90 Y SPECT/CT. The patient's SPECT/CT simulating a pretreatment 90 Y procedure accurately represented the posttreatment 90 Y microsphere distribution. Conclusions: Quantitative SPECT/CT of 100 MBq 90 Y could accurately estimate LSF, T/N, parenchymal and tumor dose, and visualize extrahepatic depositions.
INTRODUCTION
Prior to 90 Y radioembolization treatment of liver tumors, a dosage of 99m Tc-macroaggregated albumin ( 99m Tc-MAA) is administered to simulate the distribution of the 90 Y-loaded microspheres. This pretreatment safety procedure is mainly performed to estimate the lung shunt fraction (LSF) and to detect potential extrahepatic depositions. 1 In addition, a single photon emission computed tomography/computed tomography (SPECT/CT) scan of 99m Tc-MAA may be used for intrahepatic dosimetry. 2 The prescribed activity of 90 Y microspheres can be calculated based on the body surface area (BSA)-method for resin microspheres or the mono-compartment model for glass microspheres. 3, 4 Both methods assume a uniform dose distribution within the (targeted) liver volume, and thereby neglect individual patient's dose distribution. Another model to calculate prescribed activity is the partition model, which takes the average tumor to nontumor ratio into account. 5 However, this method may still be an oversimplification in the case of multiple tumors with varying uptake. 2 As an alternative to the tumor to nontumor ratio, the tumor dose may be maximized based on the maximal parenchymal dose. 6 All image-based dosimetry methods rely on the accuracy of the pretreatment procedure, which is often limited in case of 99m Tc-MAA. Observed differences in 99m Tc-MAA and 90 Y-microsphere distributions could be caused by their differences in shape and size and by free circulating pertechnetate. [7] [8] [9] A better representation of the microsphere distribution may be achieved by using identical particles for pretreatment and treatment, as is feasible in 166 Ho microsphere radioembolization. 10, 11 A similar objective may be pursued for 90 Y-loaded microspheres. However, the total energy absorbed per Bq is higher for 90 Y than for 166 Ho, which limits the pretreatment activity to the estimated safety threshold of 100 MBq. [11] [12] [13] In addition, SPECT of 90 Y is based on Bremsstrahlung imaging, which prevents the use of a photopeak energy window and energy window based scatter correction. Quantitative SPECT can be accomplished by applying Monte Carlo based reconstruction. 14 Alternatively, 90 Y may be imaged using positron emission tomography (PET). However, the small positron branching ratio of 90 Y in combination with the required low activity for pretreatment makes PET challenging.
In an earlier study, we demonstrated the feasibility of accurately estimating the LSF of a low activity 90 Y-based pretreatment procedure when imaged with SPECT/CT and reconstructed with a Monte Carlo-based reconstruction model to include scatter correction. 13 In the present study it was investigated whether low activity 90 Y SPECT/CT and PET/CT allowed detection of extrahepatic depositions and intrahepatic dosimetry, using an anthropomorphic phantom and short acquisition scans of a clinical patient to simulate a 90 Y pretreatment scan.
MATERIALS AND METHODS

2.A. Phantom
We used an anthropomorphic thorax phantom (model ECT/TOR/P, IEL, Chilcompton, UK) with a liver compartment, lung compartments (filled with styrofoam beads), and a spine insert. Two tumor compartments were added to the liver (one solid and one necrotic tumor) and three extrahepatic depositions were added to the background volume. The extrahepatic depositions were located posterior to the liver and below the left lung (small extrahepatic deposition), posterior to the liver and below the right lung (medium sized extrahepatic deposition) and above the liver and in between the lungs (large extrahepatic deposition; Fig. 1 ).
The phantom was filled with 2.0 GBq 90 Y chloride in 0.5 M of HCl to prevent adhesion to the plastic phantom walls. 15 The initial activity, size, and shape of all compartments are listed in Table I . The phantom had a LSF of 5.3% and a tumor to nontumor ratio (T/N) of 7.9. Based on the results of a previous study by Prince et al., the activity concentration of the extrahepatic depositions was chosen to be 1.3% of the total activity in the phantom divided by 6.8 mL. 11 To represent the current clinical pretreatment procedure using 99m Tc-MAA, the phantom was filled in a similar manner as described above with 99m Tc, with a total phantom activity of 153 MBq, an LSF of 5.2%, and a T/N of 7.6.
2.B. Image acquisition
Thirteen PET/CT and SPECT/CT scans were acquired of the anthropomorphic phantom as the 90 Y activity decayed from 1999 MBq down to 24 MBq. The total activity of the phantom at the time of imaging is listed in Table II . For all scans, a CT scan was made for attenuation correction and to support delineation.
All 90 Y PET/CT images were acquired on a Siemens Biograph mCT time of flight (TOF) scanner. Two bed positions were scanned to fit the entire phantom in the field of view. Acquisition time was 15 min per bed position, resulting in a total acquisition time of 30 min. Consecutive bed positions overlapped approximately 43%.
All 90 Y SPECT/CT images were acquired on a dual-head Siemens Symbia T16 scanner. Photons were acquired in a 50-250 keV energy window with the high-energy collimators mounted. Projections were acquired for 30 s per angle, using The 99m Tc SPECT/CT image was acquired on a dual-head Siemens Symbia T16 scanner. Photons were acquired in a 129-150 keV photopeak window and a 108-129 keV lower scatter window with the low-energy high-resolution collimators mounted. Projections were acquired for 20 s per angle, using 120 angles over 360 degrees, resulting in a total acquisition time of 20 min.
For 90 Y SPECT a single background measurement was performed without the phantom present using the settings described above. For 90 Y PET, a single long background measurement (total scan time of 24 h) was performed with the phantom without activity in the scanner. These background measurements were used to perform background corrections.
2.C. Image reconstruction
90 Y PET projections were reconstructed with an Ordinary Poisson Ordered Subset Expectation Maximization (OP-OSEM) reconstruction algorithm, including resolution recovery (TrueX), TOF information, random, attenuation, scatter, dead time, and decay correction. The reconstruction used four iterations with 21 subsets, and a 5 mm full width at half maximum (FWHM) Gaussian postreconstruction filter was applied.
The reconstructed voxel size was 4.1 9 4.1 9 3 mm 3 . The background measurement was reconstructed using the same settings. Background correction was performed by subtraction (for mean or summed values) or quadratic addition (for standard deviations) of the reconstructed activity in the volumes of interest (VOIs) of the background reconstruction, from the reconstructed activity in the VOIs of the 90 Y reconstruction. 90 Y SPECT projections were reconstructed with a Monte Carlo (MC) based OSEM reconstruction algorithm, including attenuation correction, resolution recovery, and MC-based scatter correction. The background correction was performed by adding the average measured background count to the forward projection. Since MC-based reconstructions take longer to converge, the reconstruction used 60 iterations with eight subsets, and an 8 mm FWHM Gaussian postreconstruction filter was applied. 14 The reconstructed voxel size was 4.8 9 4.8 9 4.8 mm 3 .
99m Tc SPECT projections were reconstructed using an OSEM reconstruction algorithm with flash3D, dual energy window scatter correction, and attenuation correction. The reconstruction used six iterations with eight subsets, and a 5 mm FWHM Gaussian postreconstruction filter was applied.
The reconstructed voxel size was 2.4 9 2.4 9 2.4 mm 3 .
2.D. Analysis
The liver, lungs, tumors, and extrahepatic depositions were semi-automatically delineated on one CT scan using 3D Slicer. 16 The reference CT was rigidly registered to all other CT scans, and all VOIs were transformed accordingly, to ensure that the same volume was analyzed for each scan. Registrations and transformations were performed using Elastix and were visually inspected. 17 The liver, lungs, and extrahepatic deposition VOIs were dilated by the spatial resolution of each system (14 mm for 90 Y SPECT and 6 mm for 90 Y PET and 99m Tc SPECT) to partially compensate for the partial volume effect. For 90 Y SPECT the dilation resulted in overlapping lung and liver VOIs, and the liver VOI was chosen to have priority over the lung VOI (as is custom in clinical practice).
2.D.1. Mono-compartment model
The mono-compartment model uses the LSF to calculate the prescribed activity for radioembolization. The LSF was calculated as: where C lung is the total number of counts in the dilated lung VOI and C liver is the total number of counts in the dilated liver VOI. In addition, potential extrahepatic depositions need to be detected in a pretreatment scan. As a measure for detectability, the contrast to noise ratio (CNR) for each extrahepatic deposition was calculated as:
where extrahepatic depostion is the mean pixel value of the nondilated extrahepatic deposition VOI, background is the mean pixel value of the background VOI (defined as the entire phantom minus the dilated VOIs of the liver, lungs and extrahepatic depositions), and S background is the standard deviation of the background VOI. The low count rate, and the ensuing high noise level, may induce false positive detection of extrahepatic depositions. To identify the presence of such false positives, spherical VOIs with the same size as the extrahepatic depositions were centered on all voxels within the phantom background VOI, and the associated CNR of these background spheres was calculated using Eq. (2), where the background is defined as the background VOI minus the background sphere. An extrahepatic deposition was considered to be detectable when its CNR was twice that of the largest CNR of the background spheres.
2.D.2. Multi compartment model
Another way to calculate the prescribed activity for radioembolization is by using the partition model, which in addition to the LSF, uses the T/N. To calculate the T/N, a parenchymal VOI was created by subtracting the tumor VOIs from the liver VOI. T/N was calculated as:
where tumor is the mean pixel value of the nondilated tumor VOI and parenchyma is the mean pixel value of the nondilated parenchymal VOI. The prescribed activity for radioembolization can also be based on a threshold for parenchymal dose and/or tumor dose. The predicted dose per GBq injected 90 Y was calculated as:
where C target is the total number of counts in the nondilated target VOI. The target is either the parenchyma, solid tumor or necrotic tumor. Fifty is the absorbed energy in joules from the decay of 1 GBq of 90 Y, and m target is the mass of the target VOI in kg (determined using the target VOI and a conversion factor of 1.03 g/mL). 12 C total is the total number of reconstructed counts and was defined as:
This definition of C total is based on the assumption that all injected activity ends up in either the liver or the lungs, and that for this particular phantom there is also activity located in the extrahepatic depositions.
The SPECT reconstructions were calibrated against an external source to yield Bq/mL by scaling the total number of reconstructed counts to the injected activity. The PET reconstructions already provide Bq/mL and thus it was possible to directly calculate the dose per GBq injected 90 Y as:
where A target is the activity in the nondilated target VOI in GBq and A total is the known total activity in the phantom in GBq.
2.D.3. Voxel-based dosimetry
Two additional metrics to those that could be used for the calculation of prescribed activity were analyzed. These are the CNR of the tumors, calculated according to Eq. (2), where the background is the parenchyma VOI eroded by the spatial resolution of each system, and the background variability (BV) of the parenchyma calculated as:
where S parenchyma is the standard deviation of the parenchyma VOI eroded by the spatial resolution of each system and parenchyma is the mean pixel value of the parenchyma VOI eroded by the spatial resolution of each system.
2.E. Patient dosimetry
To evaluate the image quality for a more inhomogeneous activity distribution, one patient who underwent radioembolization with 90 Y-doped glass microspheres (TheraSphere, BTG International Ltd.) gave informed consent to receive additional scans. The patient received a total of 3.87 GBq shortened acquisition time of 1 s per view (instead of 30 s per view) to simulate a pretreatment scan of 100 MBq 90 Y. A SPECT background measurement was performed with an acquisition time of 29 s per view. These background projections were added to the 1 s/view projections to ensure the right noise level. Prior to performing the clinical scan, we tested whether a short scan accurately mimics a low activity scan by acquiring additional short acquisitions of the anthropomorphic phantom at 1984, 1182, and 711 MBq, and comparing the metrics described above with the anthropomorphic scan acquired at 100 MBq.
Liver VOIs were manually drawn on the low dose CTs and were split into two VOIs: a high-dose (HD) and a low-dose (LD) VOI. The HD VOI included all voxels with a concentration greater than twice the average liver activity concentration on one of the reconstructed images; the LD VOI included all remaining liver voxels. The SPECT and PET reconstructed counts were converted into units of activity by normalization of the total counts in the liver VOI to the activity administered to the patient. The absorbed dose images assumed that all emitted energy was absorbed within the voxel of origin. Mean absorbed dose and cumulative dose volume histograms were calculated for both VOIs. Y PET and 90 Y SPECT clearly visualized the solid and necrotic tumor, as well as all extrahepatic depositions. The PET reconstruction had a higher spatial resolution than the SPECT reconstruction, which led to a more apparent "cold" core of the necrotic tumor. At~100 MBq, noise started to prevail in the PET reconstruction and the extrahepatic depositions were not visible anymore. However, for the SPECT reconstruction at~100 MBq, all extrahepatic depositions were still visible. For 99m Tc SPECT, both tumors and the extrahepatic depositions were clearly visible. Figure 3 (a) shows the LSF as a function of phantom activity. PET accurately estimated the LSF [absolute difference < 1 percent point (pp)] for activities over~1 GBq, and overestimated the LSF for activities below~1 GBq. SPECT accurately estimated the LSF (absolute difference < 1 pp) for activities over~50 MBq. The 99m Tc SPECT estimated an LSF of 5.0% (where the true LSF was 5.2%). Figure 3(b) shows the CNR for the extrahepatic depositions within the phantom. For both PET and SPECT the CNR of the extrahepatic depositions decreased with the phantom activity. SPECT had a higher CNR than PET, over the entire range of phantom activities. The CNR of the 99m Tc SPECT was slightly higher than the CNR of 90 Y SPECT at 100 MBq. Table III shows the minimal total activity at which the extrahepatic depositions were detectable. The smaller the extrahepatic deposition, the larger the minimal total activity needed. For SPECT, all extrahepatic depositions were detectable at the activity that would theoretically be safe to use for a 90 Y-based pretreatment scan (100 MBq). larger than the estimated dose of the necrotic tumor, although differences were smaller for PET than for SPECT. For total activities over~100 MBq, PET estimated doses of the tumors were larger than SPECT estimated doses of the tumors. For activities below~150 MBq, PET estimated doses of the tumors started to decrease. SPECT estimated doses of the tumors were more stable over the entire range of activities. The 99m Tc SPECT showed a similar estimated dose of the tumors as the 90 Y SPECT. Figure 4 (c) shows the T/N of the phantom. The observed trends were very similar to the trends observed for the estimated tumor dose. Figure 5 (a) shows the CNR of the solid and necrotic tumor. For both PET and SPECT the CNR decreased with decreasing phantom activity. SPECT had a higher CNR than PET, over the entire range of phantom activities. The solid tumor had a higher CNR than the necrotic tumor, for both modalities. The CNR of the tumors of the 99m Tc SPECT was considerably higher than the CNR of the tumors of the 90 Y SPECT at~100 MBq. Figure 5(b) shows the background variability (BV) of the parenchyma. For both PET and SPECT, the BV increased with decreasing phantom activity. The BV of SPECT was lower than the BV of PET for the entire range of phantom activities. The BV of the 99m Tc SPECT was considerably lower than the BV of the 90 Y SPECT at~100 MBq.
RESULTS
3.A. Phantom study
3.A.1. Mono-compartment model
3.A.2. Multi compartment model
3.A.3. Voxel-based dosimetry
3.B. Patient dosimetry
The method of adding a background measurement to the measured sinogram to achieve the right noise level for a simulated low activity scan for SPECT was tested with the anthropomorphic phantom. It showed that the simulated low activity scans acquired at a true total activity of 1984, 1182 and 711 MBq resemble a measured low activity scan of 100 MBq quite well in terms of LSF (difference <0.1 pp), parenchymal dose (difference <0.5 Gy/GBq) and tumor dose (difference <20 Gy/GBq). We therefore conclude that the simulated 100 MBq scan of the patient was a good indicator for the image quality of a 90 Y-based pretreatment scan. Figure 6 shows the dose volume histograms and the axial slices of the dose maps of the SPECT scan of the patient at long and short acquisitions times. Visually, the dose maps were very similar. Quantitatively, the dose volume histograms were similar and the mean dose for the LD and HD VOIs were in close agreement (mean doses HD: 497 and 518 Gy, mean doses LD: 32.5 and 28.1 Gy, D50% HD: 405 and 407 Gy, D50% LD: 3.6 and 1.8 Gy, for long and short acquisition times respectively). Figure 7 shows the dose volume histograms and the axial slices of the dose maps of the PET scan of the patient at long and short acquisition times. Visually, the short acquisition reconstruction was a lot noisier than the long acquisition reconstruction. Although the mean doses for the LD and HD VOIs were relatively comparable, the dose volume histograms showed differences, implying substantial differences in dose distribution (mean doses HD: 608 and 663 Gy, mean doses LD: 16.0 and 6.2 Gy, D50% HD: 482 and 328 Gy, D50% LD: 2.0 and 0.0 Gy, for long and short acquisition times respectively).
DISCUSSION
This study showed that the image quality of a 90 Y pretreatment SPECT/CT scan (100 MBq), when reconstructed with an MC-based reconstruction model, was sufficiently accurate for LSF, T/N, parenchymal, and tumor dose estimation and that extrahepatic depositions could be detected. A simulated 90 Y pretreatment (100 MBq) SPECT/CT scan of a radioembolization patient showed accurate dosimetry. Furthermore, our previous results on accurate LSF estimation with 90 Y SPECT/CT were confirmed. 13 The estimates of T/N and tumor dose were lower than the true T/N and tumor dose for both PET and SPECT, even at high phantom activities. This is caused by the partial volume effect. PET has a higher spatial resolution than SPECT and therefore the partial volume effect was more severe in SPECT than in PET (at 2.0 GBq, PET had a higher estimated T/N and tumor dose than SPECT). The partial volume effect also explains the higher estimated T/N and tumor dose of the solid tumor as compared with the necrotic tumor, since the solid tumor had a smaller surface-volume ratio than the necrotic tumor. The increase in underestimation of T/N and tumor dose at low phantom activities for PET is caused by the dominant noise component in these images (at 24 MBq, 61% of the true coincidences could be attributed to background activity).
To determine the detectability of extrahepatic depositions in a scan, ideally an observer study should be performed. Since this is not possible for a phantom study, we chose to compare the CNR of the extrahepatic depositions with the CNR of spheres placed in the cold background of the phantom, to study false positive detection. As a threshold value for detectability we chose a factor of two for the ratio between those CNRs in order to avoid background spheres that have similar visibility as the extrahepatic depositions.
The clinical standard for the pretreatment procedure is the use of 99m Tc-MAA. 99m Tc, with its single photopeak, is easier to image than 90 Y, which has a broad Bremsstrahlung spectrum. Furthermore, 99m Tc is usually imaged with a low-energy collimator instead of the high-energy collimator used for 90 Y, and therefore 99m Tc images are expected to have a better spatial resolution. It is thus expected that a pretreatment 99m Tc-MAA SPECT will have a higher image quality than a pretreatment 90 Y SPECT. Even though image quality of pretreatment 99m Tc-MAA SPECT is superior, as followed from the CNR for the extrahepatic depositions, CNR of the tumors, and background variability of the parenchyma, the quantitative measures LSF, T/N, parenchymal, and tumor dose were comparable for both 99m Tc and 90 Y pretreatment scans. Current guidelines on dosage calculation from the manufacturers of microspheres are all based on a mono-compartment model and advise to determine the LSF before proceeding with radioembolization treatment. 3, 4, 18 This makes the LSF the most significant metric of this study for current clinical practice. A different approach to dosage calculation is to use a multi-compartment model, which would be more personalized. This requires a T/N ratio (partition model) for dosage calculation. The downside of using the T/ N ratio is that there is currently no consensus on how to calculate the T/N and how to deal with multiple tumors. 2 Chiesa et al. 6 proposed to use a multi-compartment model using the parenchymal dose as input for dosage calculation. Both LSF and parenchymal dose are metrics that could be accurately estimated by 90 Y SPECT in this study. When moving toward voxel level estimates, a metric like the background variability (BV) becomes important. The BV favors the 99m Tc SPECT, which has a considerably lower BV than 90 Y SPECT. However, the dose volume histograms of the From a biological point of view, it is expected that using 90 Y microspheres instead of 99m Tc-MAA for the pretreatment procedure will lead to a distribution that is more similar to the treatment procedure, since the same particle is used for the pretreatment and treatment procedures. In combination with accurate imaging, this can lead to more accurate dose planning. However, since microspheres are not metabolized, 19 the microspheres administered during a pretreatment procedure will still be present in the liver vasculature during the treatment procedure, which could change the vasculature and limit the prognostic value of the pretreatment procedure. It may be important to not only limit the activity of the pretreatment procedure to avoid unintended radiation damage, but also to limit the number of microspheres administered to avoid an embolic effect. The ideal number of microspheres that should be used for a pretreatment procedure needs further investigation.
A limitation of our study is that, owing to practical reasons, only one phantom configuration was scanned. The extrahepatic depositions all had the same activity concentration, and only three depositions were inserted in our phantom. The volumes of our extrahepatic depositions covered the lower end of the range of extrahepatic depositions described by Prince et al. (1.1-41.3 mL). 11 The same holds for the activity, where our extrahepatic depositions contained 0.35%, 0.76%, and 1.52% of the total activity, while Prince et al. found extrahepatic deposition activity ranging from 0.1% to 19.5%. Although based on this phantom experiment we cannot state that all extrahepatic depositions found by Prince et al. (on 99m Tc-MAA SPECT) would be visible on a 100 MBq 90 Y SPECT, the majority of these extrahepatic depositions would likely be visible, because our phantom was on the lower end of both volume and activity, and we can assume that larger and/or more active extrahepatic depositions will be easier to visualize.
Due to the single phantom configuration, this study only investigated image quality of a phantom representing a radioembolization patient with a T/N of 7.9. A wide range of T/N has been reported in patients. 5, 20 The results from this study cannot be directly extrapolated to distributions with other T/N, although the CNR of the tumors would most likely go down for tumors with a lower T/N.
Another limitation of the phantom is that the activity distribution within the phantom compartments was uniform, and did not represent a clinical setting. Therefore, we included a patient scan to evaluate the image quality for a more inhomogeneous activity distribution. There is no ground truth distribution for the patient scan, however, compared to the long acquisition time scan, results were comparable.
The SPECT data were reconstructed with an MC-based reconstruction algorithm, which is currently not available for clinical practice. However, the image quality of the 90 Y SPECT scan relies heavily on the scatter correction offered by the MC-based reconstruction model, which has also been implemented by other groups. 21, 22 For availability of the MCbased reconstruction algorithm, please contact the authors.
A next step toward implementation of a 90 Y-based pretreatment procedure would be a patient study with several patients who receive both a pretreatment 99m Tc-MAA SPECT and a pretreatment 90 Y SPECT for comparison. Another option is to simulate the pretreatment 90 Y SPECT using a short acquisition time as was done in this study.
CONCLUSIONS
In this phantom study, a 90 Y pretreatment SPECT/CT scan (100 MBq), reconstructed with a Monte Carlo-based reconstruction model, was found to have a similar quantitative accuracy as 99m Tc-MAA SPECT/CT in estimating LSF, T/N, parenchymal, and tumor dose, while it can also visualize extrahepatic depositions. The image quality of a simulated 90 Y pretreatment scan of a patient was visually and quantitatively similar to the posttreatment scan. Author to whom correspondence should be addressed. Electronic mail: b.kunnen@umcutrecht.nl; Telephone: +31 88 7567571; Fax: +31 88 7555491.
